The SAFE Prospective Registry
Recruiting · NCT05794464 · Interventional (participants receive a specific treatment) · Lead sponsor: University Hospital Ostrava
View the official record on ClinicalTrials.gov →Interventions studied
Catheter ablation and/or electrical cardioversion
What this trial is about
Secretoneurin (SN) is a neuropeptide from the chromogranin family that influences intracellular calcium handling. SN suppresses calcium leakage from the sarcoplasmic reticulum through the ryanodine receptor. SN is a novel biomarker that has shown the potential to predict adverse arrhythmic events.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Atrial fibrillation (Afib); (paroxysmal, persistent)
- Patients indicated for catheter ablation and/or electrical cardioversion
- Signed informed consent
Exclusion criteria
- Longstanding or permanent atrial fibrillation
- Severe mitral regurgitation
- Heart failure with a permanently reduced ejection fraction
- Cerebral ischaemic stroke in \< 3 months
- Severe kidney injury
- Severe renal insufficiency
- Hepatic insufficiency limiting biomarker sampling
- Myocardial infarction \< 3 months
Where it is running
1 location listed.
- University Hospital Ostrava - Ostrava, Moravian-Silesian Region, Czechia